Showing results (91-100 of 290) with videos related to
Sort By:
Pageof 29
Journal of Clinical Pathology|October 27, 2015
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targetsHwajeong Lee, Kai Wang, Adrienne Johnson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2015
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing ApproachesAlexander Drilon, Lu Wang, Maria E Arcila, et al.The Oncologist|December 7, 2014
Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of originJuliann Chmielecki, Jeffrey S Ross, Kai Wang, et al.Plos Computational Biology|February 8, 2018
A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normalJames X Sun, Yuting He, Eric Sanford, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2010
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancerEric B Haura, Alejandro D Ricart, Timothy G Larson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancerVincent A Miller, David H Johnson, Lee M Krug, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2011
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinibGeoffrey R Oxnard, Yelena Y Janjigian, Maria E Arcila, et al.Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinibLeora Horn, Scott Gettinger, D Ross Camidge, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinibSai-Hong Ignatius Ou, Michele Azada, David J Hsiang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 18, 2011
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutationsGregory J Riely, Melissa L Johnson, Chanoa Medina, et al.Pageof 29